Report overview
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
This report aims to provide a comprehensive presentation of the global market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adeno-Associated Virus (AAV) Vector-Based Gene Therapy. This report contains market size and forecasts of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in global, including the following market information:
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Single-stranded AAV (ssAAV) Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy include BioMarin Pharmaceutical, Sangamo Therapeutics, Amicus Therapeutics, Roche, Pfizer, NightstaRx, MeiraGTx, Sarepta Therapeutics and Neurocrine Biosciences, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Segment Percentages, by Type, 2022 (%)
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Segment Percentages, by Application, 2022 (%)
Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, market overview.
Chapter 2: Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size in revenue.
Chapter 3: Detailed analysis of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
